

Michael J Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6919072/publications.pdf>

Version: 2024-02-01

217
papers

19,417
citations

19608

61
h-index

12233

133
g-index

223
all docs

223
docs citations

223
times ranked

18517
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 126-132.	2.0	6
2	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 419-426.	3.0	15
3	Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1041-1051.	3.3	22
4	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	2.8	61
5	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	3.2	28
6	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. Clinical Genitourinary Cancer, 2022, 20, 69-79.	0.9	2
7	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
8	Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	0.9	1
9	Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer, 2022, 128, 1242-1251.	2.0	11
10	Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS194-TPS194.	0.8	2
11	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.. Journal of Clinical Oncology, 2022, 40, 64-64.	0.8	0
12	Piflufolostat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. Journal of Clinical Oncology, 2022, 40, 35-35.	0.8	0
13	PSMAddition: A phase 3 trial to compare treatment with ¹⁷⁷ Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS210-TPS210.	0.8	16
14	Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS206-TPS206.	0.8	3
15	Use of bone modifying agents for metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 55-55.	0.8	0
16	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± A± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	3.2	8
17	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of Clinical Oncology, 2022, 40, 3011-3014.	0.8	12
18	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51

#	ARTICLE	IF	CITATIONS
37	Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 267-278.	1.6	10
38	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	0.9	21
39	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	0.9	2
40	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	3.2	22
41	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61.	0.2	180
42	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	2.6	11
43	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	0.8	36
44	Lutetium-177 ^α PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	13.9	1,042
45	A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 447-456.	0.9	3
46	Attenuation of SRC Kinase Activity Augments PARP Inhibitor ^α mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1792-1806.	3.2	13
47	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>European Urology Open Science</i> , 2021, 34, 70-78.	0.2	3
48	Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 66-73.	2.0	9
49	¹¹ C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series. <i>Journal of Nuclear Medicine</i> , 2020, 61, 827-833.	2.8	18
50	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 222-229.e2.	0.9	5
51	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1167-1179.	1.5	28
52	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , 2020, 126, 5311-5318.	2.0	13
53	Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2020, 5, e000943.	2.0	2
54	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16

#	ARTICLE	IF	CITATIONS
55	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3230-3238.	3.2	112
56	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.	1.4	1
57	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted $\hat{1}\pm$ -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	3.3	16
58	Docetaxel for Early Prostate Cancer: What Have We Learned?. <i>European Urology</i> , 2020, 77, 573-575.	0.9	4
59	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 507-516.	2.0	10
60	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 171-178.e2.	0.9	25
61	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	0.8	107
62	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
63	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020, 78, 671-679.	0.9	72
64	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020, 4, 355-366.	1.5	93
65	Impact of PSMA-targeted imaging with ^{18}F -DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5501-5501.	0.8	21
66	Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5565-5565.	0.8	11
67	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263.	1.0	8
68	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019, 292, 273-286.	3.6	46
69	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
70	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>European Urology Oncology</i> , 2019, 2, 605-616.	2.6	30
71	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
72	Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1504-1506.	2.8	62

#	ARTICLE	IF	CITATIONS
73	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	1.1	10
74	Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 306-314.	0.9	2
75	Pharmacokinetics and Biodistribution of a [⁸⁹ Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Molecular Pharmaceutics</i> , 2019, 16, 3083-3090.	2.3	26
76	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹ Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1517-1523.	2.8	38
77	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	1.3	42
78	Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 522-530.	2.0	15
79	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1221-1227.	2.8	10
80	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 1052-1060.	1.2	11
81	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	0.8	83
82	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 471.	3.4	426
83	Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 324-330.	2.0	13
84	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	2.0	8
85	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	2.8	23
86	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 309-316.	2.0	14
87	Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5008-5008.	0.8	31
88	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
89	±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies”Part 2. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1020-1027.	2.8	72
90	Reproducibility and Repeatability of Semiquantitative ¹⁸ F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1516-1523.	2.8	20

#	ARTICLE	IF	CITATIONS
91	Current perspectives on bone metastases in castrate-resistant prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 189-196.	2.7	66
92	Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?. <i>Cancer</i> , 2018, 124, 1326-1334.	2.0	39
93	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. <i>Prostate</i> , 2018, 78, 775-789.	1.2	35
94	Î±-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studiesâ€”Part 1. <i>Journal of Nuclear Medicine</i> , 2018, 59, 878-884.	2.8	131
95	Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. <i>BJU International</i> , 2018, 121, 534-539.	1.3	13
96	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
97	Longâ€”Half-Life ⁸⁹ Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 399-402.	2.8	9
98	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
99	Positron Emission Tomography/Computed Tomographyâ€”Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93
100	Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 355-362.	1.8	28
101	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1539.	0.8	51
102	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 319-322.	2.5	4
103	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 944.	3.4	86
104	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1344.	3.4	169
105	Microsatellite instability in prostate cancer and response to immune checkpoint blockade.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5020-5020.	0.8	14
106	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LCâ€”MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 197-205.	1.4	29
107	Effective Prostate-Specific Membrane Antigenâ€”Based 18F-DCFPyLâ€”Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e516-e518.	0.7	7
108	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	0.5	52

#	ARTICLE	IF	CITATIONS
109	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	0.8	584
110	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1859-1860.	0.8	1
111	Quantitative Assessment of Early [¹⁸ F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2829-2837.	0.8	52
112	Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5068-5068.	0.8	2
113	Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 154-154.	0.8	8
114	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 131-141.	1.8	19
115	Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 3S-5S.	2.8	14
116	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	3.2	46
117	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor- α Axis Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 73S-78S.	2.8	16
118	Fully automated synthesis of [¹⁸ F]fluoro- α -dihydrotestosterone ([¹⁸ F]FDHT) using the FlexLab module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 424-428.	0.5	10
119	First-in-Human Imaging with ⁸⁹ Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1858-1864.	2.8	116
120	A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1865-1871.	2.8	31
121	Repeatability of Quantitative ¹⁸ F-NaF PET: A Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1872-1879.	2.8	62
122	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e15-530.e21.	0.8	38
123	Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 347-352.	1.0	11
124	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , 2016, 6, 23.	1.1	37
125	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
126	Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3774-3781.	3.2	21

#	ARTICLE	IF	CITATIONS
127	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	0.8	332
128	Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 41-45.	2.8	45
129	Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5075-5075.	0.8	10
130	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 131-141.	1.8	16
131	A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). <i>EBioMedicine</i> , 2015, 2, 1814-1820.	2.7	13
132	Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. <i>Cancer</i> , 2015, 121, 3853-3861.	2.0	27
133	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
134	Targeting the androgen receptor in prostate and breast cancer: several new agents in development. <i>Endocrine-Related Cancer</i> , 2015, 22, R87-R106.	1.6	76
135	Reply to K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 3222-3223.	0.8	0
136	Failure of ELM-PC 5: An Ineffective Drug or an Unfit End Point?. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-681.	0.8	6
137	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120
138	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). <i>Cancer</i> , 2015, 121, 1025-1031.	2.0	32
139	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	3.2	163
140	Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e305-e309.	0.9	30
141	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. <i>EJNMMI Research</i> , 2015, 5, 28.	1.1	63
142	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5000-5000.	0.8	25
143	Effect of radium-223 dichloride (Ra-223) on pain from US EAP.. <i>Journal of Clinical Oncology</i> , 2015, 33, 160-160.	0.8	8
144	89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	3.3	130

#	ARTICLE	IF	CITATIONS
145	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. <i>Radiology</i> , 2014, 271, 220-229.	3.6	88
146	Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1308-1316.	0.8	46
147	Brain Metastases from Prostate Cancer: An 11-Year Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis. <i>Journal of Neuroimaging</i> , 2014, 24, 161-166.	1.0	72
148	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	13.5	1,184
149	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 671-677.	0.8	410
150	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5002-5002.	0.8	6
151	The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , 77-94.	0.0	0
152	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	0.8	34
153	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3525-3530.	0.8	223
154	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1307-1316.	5.1	205
155	Validation and clinical utility of prostate cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 225-234.	12.5	83
156	Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³ Ra-dichloride in men with castration-resistant metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1384-1393.	3.3	160
157	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
158	Repetitively dosed docetaxel and ¹⁵³ samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3186-3194.	2.0	23
159	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	2.0	17
160	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8-LBA8.	0.8	30
161	Targeting bone physiology for the treatment of metastatic prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 134-43.	0.3	8
162	Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 519-524.	0.8	162

#	ARTICLE	IF	CITATIONS
163	Computer-aided quantitative bone scan assessment of prostate cancer treatment response. <i>Nuclear Medicine Communications</i> , 2012, 33, 384-394.	0.5	45
164	When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1534-1541.	3.0	118
165	Androgen deprivation and thromboembolic events in men with prostate cancer. <i>Cancer</i> , 2012, 118, 3397-3406.	2.0	74
166	Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 174-188.	1.3	27
167	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1089-1097.	1.1	30
168	A Case Report of Putative Autoimmunity to Prostate Cancer After Immune-Mediated Rejection of Melanoma Through a Shared Tumor Antigen. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 126-129.	0.9	0
169	A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. <i>European Urology</i> , 2012, 62, 78-84.	0.9	158
170	Germline <i>BRCA</i> mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. <i>BJU International</i> , 2012, 109, 713-719.	1.3	40
171	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 763-771.	1.1	21
172	Clinical State of the Rising PSA Value after Definitive Local Therapy. , 2012, , 2921-2933.e3.		0
173	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	0.8	202
174	Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 880-887.	3.2	42
175	Developing imaging strategies for castration resistant prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 39-48.	0.8	48
176	Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1727-1732.	2.8	46
177	Reply to Tomasz Druwa and Piotr Chłosta's Letter to the Editor re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate. <i>Eur Urol</i> 2009;56:237-44. <i>European Urology</i> , 2010, 57, e20.	0.9	0
178	Harnessing Naturally Occurring Tumor Immunity: A Clinical Vaccine Trial in Prostate Cancer. <i>PLoS ONE</i> , 2010, 5, e12367.	1.1	14
179	Pharmacokinetic Assessment of the Uptake of ¹⁸ F-Fluoro-5 α -Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 183-192.	2.8	113
180	Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and ^{99m} Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 6093-6099.	3.2	130

#	ARTICLE	IF	CITATIONS
181	Germline <i>BRCA</i> Mutations Denote a Clinicopathologic Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2115-2121.	3.2	263
182	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 2 study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	6.3	972
183	Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1496-1501.	0.8	396
184	Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7421-7428.	3.2	203
185	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2436-2442.	0.8	92
186	Phase I Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer. <i>European Urology</i> , 2009, 56, 237-244.	0.9	73
187	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 51-57.	0.9	21
188	Assessing outcomes in prostate cancer clinical trials. <i>Cancer</i> , 2008, 113, 966-974.	2.0	19
189	Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732.	2.9	42
190	Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2031-2041.	2.8	118
191	Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2959-2965.	0.8	31
192	Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using ¹¹¹ In-J591: Lesion Detectability and Dosimetric Projections for ⁹⁰ Y Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1066-1074.	2.8	76
193	Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2707-2713.	3.2	73
194	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1775-1782.	3.2	198
195	Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 675-681.	0.8	102
196	Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. <i>Clinical Cancer Research</i> , 2007, 13, 5816-5824.	3.2	84
197	A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2007, 178, 2378-2384.	0.2	40
198	Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 658-667.	4.3	57

#	ARTICLE	IF	CITATIONS
199	Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 536-537.	4.3	1
200	Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. <i>Translational Medicine Series</i> , 2006, , 291-313.	0.0	0
201	Safety and Biologic Activity of Intravenous BCL-2 Antisense Oligonucleotide (G3139) and Taxane Chemotherapy in Patients With Advanced Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 6-13.	0.6	24
202	Targeting osseous metastases: rationale and development of radioimmunotherapy for prostate cancer. <i>Current Urology Reports</i> , 2005, 6, 163-170.	1.0	0
203	Pilot Trial of Unlabeled and Indium-111 Labeled Anti Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 7454-7461.	3.2	120
204	Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 3210-3216.	3.2	122
205	Prostate Cancer Clinical Trial End Points: RECISTing a Step Backwards. <i>Clinical Cancer Research</i> , 2005, 11, 5223-5232.	3.2	126
206	Targeting osseous metastases: Rationale and development of radioimmunotherapy for prostate cancer. <i>Current Oncology Reports</i> , 2004, 6, 222-229.	1.8	0
207	High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. <i>Cancer</i> , 2004, 100, 1868-1875.	2.0	39
208	Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 21-31.	2.0	4
209	Clinical Approaches to Osseous Metastases in Prostate Cancer. <i>Oncologist</i> , 2003, 8, 161-173.	1.9	32
210	Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. <i>Urology</i> , 2002, 59, 913-918.	0.5	203
211	Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. <i>Surgical Oncology</i> , 2002, 11, 13-23.	0.8	15
212	HER-2 profiling and targeting in prostate carcinoma. <i>Cancer</i> , 2002, 94, 980-986.	2.0	128
213	HER-2 profiling and targeting in prostate carcinoma. , 2002, 94, 980.		1
214	Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2002, 8, 679-83.	3.2	132
215	Novel strategies and therapeutics for the treatment of prostate carcinoma. <i>Cancer</i> , 2000, 89, 1329-1348.	2.0	48
216	RECOGNIZING ABNORMAL MARKER RESULTS THAT DO NOT REFLECT DISEASE IN PATIENTS WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 2000, 163, 796-801.	0.2	37

#	ARTICLE	IF	CITATIONS
217	High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering experience (1988-1999). , 1999, 83, 834-838.		12